Business Context and Reporting Period
Organon & Co. filed a Form 8-K dated June 2, 2021, reporting completion of its separation from Merck & Co., Inc. Organon became a standalone public company comprising Merck’s women’s health, biosimilars and established brands businesses. Regular-way trading of Organon common stock began on the NYSE on June 3, 2021, under the symbol OGN.
Merck distributed all outstanding Organon shares pro rata to Merck shareholders of record on May 17, 2021, at a ratio of one-tenth of an Organon share for each Merck share held. Fractional shares were settled in cash.
Financial Metrics, Debt and Liquidity
- The filing does not provide current-period revenue, profit, cash flow, margins or balance-sheet liquidity metrics.
- Organon assumed obligations under notes issued in April 2021 totaling €1.25 billion of 2.875% senior secured notes due 2028, $2.1 billion of 4.125% senior secured notes due 2028 and $2.0 billion of 5.125% senior unsecured notes due 2031.
- Organon entered into a senior credit agreement providing for a $3.0 billion U.S. dollar-denominated Term Loan B, a €750 million euro-denominated Term Loan B, both maturing in 2028, and a $1.0 billion revolving credit facility maturing in 2026.
- Initial pricing was generally 3.00% over Adjusted LIBOR or 2.00% over the alternate base rate for U.S. dollar term loans, 3.00% over Adjusted EURIBOR for euro term loans, and 2.00% over applicable reference rates for revolving loans. The unused revolving commitment fee initially was 0.50%.
- The revolving facility includes quarterly total-leverage-ratio testing and customary restrictions on additional debt, acquisitions, dividends, equity repurchases, liens and other transactions.
Material Changes Versus the Prior Comparable Period
- Organon transitioned from a Merck business to a separately traded company through the June 2, 2021 distribution.
- Merck’s Retained Products Segment was excluded from Organon and retained by Merck. The filing refers investors to incorporated unaudited pro forma financial information for the resulting presentation.
- Organon assumed the principal obligations under the notes, with a Dutch co-issuer and specified Organon subsidiaries acting as guarantors.
- Merck and Organon entered into separation, tax, employee matters and reciprocal transition services agreements. Transition services generally run for no more than 25 months, subject to early termination rights.
- Organon adopted new governance documents, appointed a 13-member board including continuing director Shalini Sharp, and confirmed its executive leadership team.
Guidance, Outlook, Risks and Unusual Items
- The filing does not provide revenue or earnings guidance.
- The Tax Matters Agreement allocates pre-distribution and separation-related tax responsibilities between Merck and Organon. Organon is generally responsible for taxes attributable exclusively to its business and certain liabilities arising from breaches of its representations or covenants.
- For two years after the distribution, Organon and its subsidiaries are subject to restrictions intended to preserve the tax-free treatment of the separation, including limitations on certain acquisitions, mergers, equity issuances, stock repurchases and asset transactions.
- The separation agreements include cross-indemnities, insurance allocations and procedures for ongoing litigation and other liabilities. The filing does not quantify potential indemnification or litigation exposure.
- Transition services create temporary operational dependence on Merck and include information technology, human resources, finance, regulatory, supply chain, distribution and promotional support.
- The company adopted incentive, annual bonus and executive severance and change-in-control programs. Specific potential compensation amounts are not provided in the filing text.
Investor Verification Checklist
- Review the incorporated Information Statement and unaudited pro forma financial information for Organon’s standalone historical results and adjustments for the Retained Products Segment.
- Verify the full terms, collateral, guarantees, covenants and mandatory repayment provisions of the notes and Senior Credit Agreement.
- Assess leverage, interest expense, refinancing needs and compliance with the revolving facility’s total-leverage covenant once standalone financial statements are available.
- Review the Tax Matters Agreement for separation-related tax exposure and the two-year restrictions affecting corporate transactions and capital allocation.
- Evaluate reliance on Merck transition services and the cost and execution risk of replacing those services before their scheduled termination.
- Review the separation and indemnification agreements for litigation, employee, insurance and other liabilities transferred to Organon.